y Type 1: Phase 3 Results. Presented at: SLEEP 2026; 14-17 June 2026; Baltimore, MD.
4 The topline results of these studies were shared on September 8, 2025, in “Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025.”
5 Crawford S, et al. Sleep 2024;47(suppl 1):A288.


View source version on businesswire.com: https://www.businesswire.com/news/home/20260615651327/en/


CONTACT:

Investor Relations

Christopher O’Reilly
takeda.ir.contact@takeda.com

Media Relations

Tsuyoshi Tada (Tokyo)
Toiawase_kouhou@takeda.co.jp

Kristi Bond (Boston)
Media_relations@takeda.com


=*=*=*=*=*=
当前为第14/14页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页